1Stamler J,Vaccaro O, Neaton JD, et al. Diabetes, other risk factors,and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial[J]. Diabetes Care,1993,16(2):434-444.
2Pickup JC,Crook MA. Is type Ⅱ diabetes mellitus a disease of the innate immune system? [J]. Diabetologia, 1998, 41 (10) :1241-1248.
3Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X[J].Diabetologia, 1997,40 (11) :1286-1292.
4Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein,interleukin 6, and risk of developing type 2 diabetes mellitus[J]. JAMA,2001,286(3) :327-334.
5Kang ES, Kim HJ, Kim YM, et al. Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes[J]. Diabetes Res Clin Pract,2004,66(suppl 1):s115-120.
7Sigurdardottir V, Fagerberg B, Hulthe J Preclinical atheroselerosis and inflammation in 61-year-old men with newly diagnosed diabetes and established diabetes[J]. Diabetes Care,2004,27(4) :880-884.
8Moussavi N, Renier G, Roussin A, et al. Lack of concordance between plasma markers of cardiovascular risk and intimamedia thickness in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2004,6 (1) : 69-77.
9Calandra T,Bernhagen J, Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor[J]. J Exp Med, 1994,179(6) : 1895-1902.
10Colwell GA. Inflammation and diabetic vascular complications[J]. Diabetes Care,1999,22(12) :1927-1928.
二级参考文献17
1BASTARD J P,PIERONI L,HAINQUE B.Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance [J].Diabetes Metab Revs Rev,2000,16(3):192-201.
2ASO Y,MATSUMOTO S,FUJIWARA Y,et al.Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes:association with increased plasminogen activator inhibitor-1 [J].Metabolism,2002,51(4):471-476.
3PICK J C,CROOK M A.Is type 2 diabetes mellitus a disease of the innate immune system?[J].Diabetologia,1998,41(10):1241-1248.
4ROSS R.Atherosclerosis an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
5CARANTONI M ZULIANI G,VOLPATO S,et al.Relationships between fasting plasma insulin,anthropometrics,and metabolic parameters in a very old healthy population[J].Metabolism,1998,47(5):535-540.
6NORDT T K,SAWA H,FUJI S,et al.Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo [J].J Mol Cell Cardiol,1998,30(8):1535-1543.
7KATO K,SATOH H,ENDOY T,et al.Thiazolidinediones down regulates plasminogen activator inhibitor type1 expression in human vascular endothelial cells:a possible role for PPAR-gamma in endothelial function [J].Biochem Biophys Revs Commune,1999,258(2):431-435.
8ALJADA A,GARG R,GHANIM H,et al.Nuclear factor-Kappa B suppressive and inhibitor-Kappa B stimulatory effects of troglitazone in obese patients with 2 diabetes:evidence of an anti-inflammatory action?[J]. J Clin Endocrine Metab,2001,86(7):3250.
9Padhan AD,Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J,2003,23:831.
10Grobbee DE,Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med,1994,236:567.
